Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 3 1

Status

Completed 3

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Breast 3CNS 1

Conditions

Triple Negative Breast Neoplasms 3Breast Neoplasms 3Recurrence 2Ovarian Neoplasms 2Neoplasms 2Hypersensitivity 2Neoplasm Metastasis 1Fanconi Anemia, Complementation Group D1 1Carcinoma, Non-Small-Cell Lung 1Breast Cancer Female 1Brain Neoplasms 1

Interventions

Trastuzumab 304Paclitaxel 257Cyclophosphamide 251Docetaxel 238Capecitabine 176Letrozole 163Carboplatin 163Fulvestrant 145Doxorubicin 145Bevacizumab 121Anastrozole 106Tamoxifen 102exemestane 94Vinorelbine 91Epirubicin 90pertuzumab 89Gemcitabine 84Lapatinib 80Albumin-Bound Paclitaxel 74Radiotherapy 71pembrolizumab 70palbociclib 64130-nm albumin-bound paclitaxel 58eribulin 56Cisplatin 55Everolimus 49pyrotinib 45Taxes 44Goserelin 43Neoadjuvant Therapy 40

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × Breast Neoplasms × iniparib × Clear all
NCT01173497 2016-03-17

A Study Evaluating INIPARIB in Combination With Chemotherapy to Treat Triple Negative Breast Cancer Brain Metastasis

Sanofi

Phase 2 Completed
44 enrolled
BreastCNS

Brain Neoplasms, Breast Neoplasms, Triple Negative Breast Neoplasms

NCT01045304 2014-01-14

Study of SAR240550 (BSI-201) in Combination With Gemcitabine/Carboplatin, in Patients With Metastatic Triple Negative Breast Cancer

Sanofi

Phase 2 Completed
163 enrolled
Breast

Breast Neoplasms, Neoplasm Metastasis

NCT00540358 2012-12-28

A Phase 2 Trial of Standard Chemotherapy, With or Without BSI-201, in Patients With Triple Negative Metastatic Breast Cancer

Sanofi

Phase 2 Completed
123 enrolled
Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡